Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
May 11, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
April 20, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLEStudy sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity...
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
March 30, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for Q2 2021Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU,...
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
March 15, 2021 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
●Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 ●Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
March 09, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, March 09, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
March 08, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
• Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET Norwood, MA, March 08, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...
Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
January 20, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Presentations about compounds in Corbus’ pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist...
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
November 12, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
November 10, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company intends to shorten fully-enrolled Phase 3 dermatomyositis trial to 28 weeks from 52 weeks following recent developments in competitive landscape; data now expected as early as the second...
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
November 09, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data remain as previously reportedPost-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background...